Objective. To understand the relationship between opioid use in patients with congestive heart failure and outcomes, we compared length of stay (LOS), 30-day readmission rates, and 30-and 90-day mortality in patients discharged with a primary diagnosis of congestive heart failure (CHF) who were taking opioids.
Introduction
Approximately 5.7 million adults in the United States have a diagnosis of congestive heart failure (CHF), and 1 million are admitted to the hospital each year [1] . Improving outcomes such as length of stay (LOS), short-term mortality rates, and 30-day readmission rates in these patients is important to hospitals and patients alike, and such outcomes are used to measure quality of care. In addition, reimbursement by insurers is linked to these outcome measures. In recent years, policymakers have increased emphasis on outcomes of patients with CHF; these outcomes are considered metrics of care, and as such, they can be used to hold hospitals accountable for the care that they provide [2] . To improve care, it is important to understand the factors that influence these outcomes.
Improving outcomes in patients with CHF is a high priority. National data show that more than 20% of patients with CHF are readmitted within 30 days, and approximately 12% of these patients die during their hospitalization [3] . Identifying risk factors associated with poor outcomes is a crucial first step in developing programs that could reduce these rates [4] . Both CHF and opioid use are known to be associated with higher rates of readmission, but their combined risk has not been studied [5] . Because opioids are often used to treat the long-term pain associated with terminal illnesses such as CHF, an understanding of how opioids affect patients with CHF and influence outcomes is needed to reduce costs and provide better care [6] .
The physiologic effect of opioids on patients with CHF is unclear. Opioids such as morphine can reduce some symptoms of late-stage CHF, including dyspnea, particularly during exercise [7, 8] . Morphine likewise appears to relieve ischemia in patients with cardiovascular risk factors [9, 10] . These findings, along with evidence that the pharmacologic mechanism of morphine produces certain beneficial peptides, has led some researchers to conclude that morphine may have some cardioprotective effects in patients with CHF [11, 12] . However, the research is contradictory; one study showed that patients with CHF who were prescribed morphine (along with nitroglycerin and/or furosemide) had reduced mortality rates [13] , yet another study showed that opioids, including morphine, have few effects on the cardiovascular system at rest [9] . Moreover, the combination of CHF and opioid use appears to increase the likelihood of cardiovascular events for patients receiving long-term opioid therapy [14] . Opioids generally have been associated with increased rates of readmission [15] . Similarly, opioid users undergoing coronary artery bypass surgery were more likely to be readmitted, although the mechanism was unclear [16] .
To better understand the relationship between opioid use and outcomes of patients with CHF, we compared LOS, 30-day readmission rates, and 30-and 90-day mortality rates in patients discharged with a primary diagnosis of CHF who were receiving opioid medications at admission, discharge, or both.
Methods
The Mayo Clinic Institutional Review Board approved this study.
Setting and Design
This retrospective study was conducted at a 320-bed academic hospital. All patients discharged with a primary diagnosis of heart failure (International Classification of Diseases, Ninth Revision [ICD-9] codes 428.0-428.9) from January 1, 2011, through December 31, 2014, were included in the study. Patients who were admitted to await heart transplant were excluded because these patients are hospitalized for the purpose of inotropic support until transplant is available and generally receive a transplant before discharge. The event of heart transplantation can change outcomes and confound the results. All data were collected from the electronic health record; demographic data included age, weight, sex, and race. Clinical data collected included cardiac ejection fraction, a history of diabetes mellitus, hypertension, coronary artery disease, cerebrovascular disease, dementia, peripheral arterial disease, chronic kidney disease, cancer, and lung and liver disease, Medical comorbidity was measured by using the Charlson Comorbidity Index (CCI) [17] . The CCI was scored electronically using diagnoses in the institution's medical index database. Death record databases were accessed for the 30-and 90-day mortality data. To determine the number of patients readmitted within 30 days, data were collected and reviewed from the Mayo Clinic electronic health records and the Medicare database of readmissions to all other institutions obtained from the Center for Medicare and Medicaid Services QNet portal for the Hospital Readmissions Reduction Program, accessed April 1, 2016. The readmission rate for our hospital for CHF patients ranges between 20% and 24% annually, considered no different from the national average (21.9%).
At our institution, all patients have a medication list generated at admission and confirmed by an admission nurse with the patient or caregiver. At discharge, the medication list is updated (medication reconciliation) and becomes a permanent part of the medical record on the date of discharge. These admission and discharge medication lists were reviewed for all opioid medications, both scheduled and as needed, including morphine, oxymorphone, hydromorphone, codeine, oxycodone, hydrocodone, methadone, fentanyl, or meperidine.
Statistical Analysis
Patient demographic characteristics and clinical data were described after stratifying by opioid use at admission and discharge by using the sample median and standard deviation for continuous variables and frequency and percent for categorical variables. The comparison of individual variables between groups with and without opioid use was completed with either a Wilcoxon rank-sum test for continuous variables or a v 2 test for independence for categorical variables. The association of opioid use at admission and discharge with 30-day readmission, 30-and 90-day mortality, and LOS was examined using logistic regression, Cox proportional hazards regression, and linear regression models, respectively. We chose to evaluate LOS as a variable with opioids at discharge because of the assumption that patients who are prescribed opioids at discharge likely are also given opioids during hospitalization, and it may therefore affect the LOS. Significant univariate associations were then tested. For logistic regression models, odds ratios (ORs) and 95% confidence intervals (CIs) were estimated. For Cox proportional hazards regression models, hazard ratios (HRs) and 95% CIs were estimated. For linear regression models, regression coefficients (parameter estimates) and 95% CIs were estimated. All statistical analyses were performed using SAS software (version 9.4, SAS Institute, Inc, Cary, NC, USA). Patient factors that have been seen to have an effect on the outcomes of interest (LOS, readmission, and mortality) and were shown to have significance in the univariate analysis were included in the multivariate analysis. These factors included age, body mass index, history of solid tumor, ejection fraction (due to CHF because of the population studied), and CCI.
Results
Six hundred eighty-two patients with a principle diagnosis of heart failure were admitted during the study period. Patients were grouped by their use of opioids at admission and at discharge ( Table 1 ). The groups were demographically similar in that they were both primarily white (overall, N ¼ 581 [85.2%]) and male (overall, N ¼ 402 [58.9%]). The mean body mass index in each group fell within the overweight category. The age range of the entire study cohort was 19 to 101 years.
Opioids at Admission
Of the 682 patients, 168 (24.6%) reported taking opioids at the time they were admitted. Compared with patients not taking opioids at admission, these patients had a mean LOS of 3.9 (SD ¼ 3.1) vs 4.1 (SD ¼ 4.2) days, 30-day readmissions of 34 (20.7%) vs 88 (17.1%) patients, 30-day mortality of 12 (7.1%) vs 40 (7.8%) patients, and 90-day mortality of 25 (14.9%) vs 80 (15.6%) patients. We did not observe any significant univariate associations between opioid use at admission and LOS, 30-day readmissions, or 30-or 90-day mortality (Table 2 ).
Opioids at Discharge
One hundred ninety-three patients (28.3%) were prescribed opioids at discharge. Compared with patients who were not prescribed opioids at discharge, these patients had a mean (SD) LOS of 4.6 (4.9) days vs 3.8 (3.6) days, a 30-day readmission rate of 37 (19.2%) vs 85 (17.4%), a 30-day mortality rate of 9 (4.7%) vs 4.3 (8.8%) patients, and a 90-day mortality rate of 23 (11.9%) vs 82 (16.7%) patients. In univariate analysis, opioid use on discharge was not associated with 30-day readmissions (OR ¼ 1.10, 95% CI ¼ 0.72-1.69, P ¼ 0.65), 30-day mortality (OR ¼ 0.51, 95% CI ¼ 0.24-1.06, P ¼ 0.07), or 90-day mortality (OR ¼ 0.67, 95% CI ¼ 0.41-1.10, P ¼ 0.12). Opioid use at discharge was associated with LOS (parameter estimate ¼ 0.78 days, 95% CI ¼ 0.12-1.45 days, P ¼ 0.02) ( Table 2 ). Multivariate logistic model analysis was then performed using the dependent variable LOS and the variables CHF ¼ congestive heart failure; NOS ¼ not otherwise specified. *Includes patients who also were receiving opioids at admission; 34 patients receiving opioids at admission did not have opioids prescribed at discharge, and 59 patients were prescribed opioids at discharge but were not receiving them at admission.
opioid use at discharge, age, body mass index, solid tumor presence, CCI score (using comorbidities included in this index), and ejection fraction. The final model showed that LOS was associated with younger age (P < 0.001) and higher CCI score (P ¼ 0.003) but was not associated with opioid use on discharge (P ¼ 0.11) ( Table 3) . Multivariate modeling was not done for the 30-day readmissions or 30-or 90-day mortality because in the univariate analysis opioids at admission and at discharge were not significant for these variables ( Table 2) .
Discussion
The objective of this study was to examine the relationship between opioid medication use in patients with CHF and hospital outcomes. We found that nearly 25% and 30% of patients with CHF were receiving opioids at admission and at discharge, respectively. In our cohort, opioid use at admission had no effect on LOS, 30-day readmissions, or 30-or 90-day mortality rates. Similarly, opioid use at discharge was not associated with 30-day readmissions, LOS, or 30-or 90-day mortality rates, but LOS was associated with younger age and higher CCI score. A patient with a higher CCI score would be expected to have a longer LOS because of multiple comorbid conditions, yet the reason for the association between younger age and increased LOS is less obvious. One possible explanation could be that younger patients were better candidates for cardiac intervention (e.g., a coronary catheterization procedure), which could result in increased LOS when compared with medication adjustment in an older patient. We also observed that patients with opioids prescribed at discharge were significantly younger; the reason for this difference is unclear. It is possible that providers are more comfortable prescribing opioids at discharge to younger patients, and many patients (N ¼ 59) who were not receiving opioids at admission were prescribed these medications at discharge.
Chronic opioid use is associated with health care utilization and specifically with hospital readmissions in the general population [16] . We did not observe an association between opioid use and 30-day readmission in A prior study showed that patients prescribed opioids for noncancer pain have a higher risk of all-cause mortality (excluding overdose), specifically cardiovascular mortality [18] . We did not find this to be the case in patients with CHF; other cardiovascular risks may increase with opioid use. Given the frequency of opioid therapy, studying outcomes in larger populations of opioid users may be beneficial to help delineate which comorbidities confer higher risk for adverse outcomes. We also found that a relatively high percentage of patients with CHF were taking opioids (24.6%), similar to that seen in general hospitalized patients [16] .
This study has several limitations. It was a retrospective study that depended on the accuracy of the health record. This single-site study had an ethnically homogeneous patient population; the findings should be validated in a multicenter population. The indications for opioid medications were not obtained from the health record, and uncovering the indications would be challenging in a retrospective study. We also did not differentiate between scheduled or as-needed dosing; there could have been differences, based on the level of opioid usage. Additionally, the study sample may have been too small to show a statistically significant difference between patients who were and were not receiving opioid medication. We were not able to retrospectively assess functional status; patients receiving opioids may have worse functional status, which could affect outcomes and confound the results. However, we did not identify worse outcomes in patients receiving opioids; even if their functional status was diminished, it did not appear to affect our outcomes of interest. We also did not assess other prescription medications, for example, those prescribed specifically for heart failure. These medications could affect outcomes, but because many medications now are used for heart failure, with varying efficacy, the effect of other medications would be difficult to analyze with respect to opioid use. However, we did use ejection fraction in our multivariate analysis for LOS.
Although we did not observe significantly different outcomes with opioids, their use in this patient population was substantial. Nearly 25% of patients were receiving opioids at admission, and nearly 30% of patients were prescribed them at discharge. Patients with CHF are commonly older and have comorbidities that increase their risk for adverse drug events and poor outcomes.
Future studies should examine in-hospital adverse events and the indications for opioid medication use in patients with CHF.
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